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Abstract 
Background: Sortilin is a 95-kDa protein which has recently been linked to circulating cholesterol concentration and 
lifetime risk of developing significant atherosclerotic disease. Sortilin is found inside different cell types and circulating 
in blood. Higher circulating sortilin concentration has been found in patients with coronary atherosclerosis compared 
to control subjects. Sortilin concentration is influenced by statin therapy.
Methods: We enrolled statin-naïve subjects with type 2 diabetes mellitus and we performed a cross-sectional study 
to evaluate the association between sortilin levels and the presence of clinically significant lower limb peripheral 
artery disease (PAD) in a population of statin-free diabetic subjects.
Results: Out of the 154 patients enrolled in our study, 80 patients were free from PAD, while 74 had clinically signifi-
cant PAD. Sortilin concentration was significantly higher in the latter group compared to the former (1.61 ± 0.54 ng/
mL versus 0.67 ± 0.30 ng/mL, P < 0.01) and there was a trend toward increased sortilin levels as disease severity 
increased. The association of sortilin levels with PAD remained after adjusting for major risk factors in a multivariate 
analysis.
Conclusions: We showed that sortilin is significantly and independently associated with the presence of lower limb 
PAD in a statin-free diabetic population and it may be a promising marker for clinically significant atherosclerosis of 
the lower limbs. Further studies are needed to confirm this finding and to evaluate its clinical usefulness.
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Background
Sortilin, a 95-kDa protein mainly expressed in hepato-
cytes, takes part in intracellular protein sorting between 
the trans-Golgi network and endosomes [1]. In a lesser 
quantity, it is also expressed on cell membrane and 
small quantities of sortilin have been found in circulat-
ing form. Sortilin is codified on chromosome 13 by the 
gene SORT1, whose polymorphisms have been linked 
with circulating levels of low-density lipoprotein (LDL) 
cholesterol and with the lifetime risk of developing clini-
cally significant atherosclerosis [2–12].
Sortilin seems to take part in apolipoproteins traffick-
ing inside hepatocytes, binding to apoB100 and pro-
moting its trafficking to endosomal system, thereby 
promoting its degradation and reducing circulating levels 
of very low-density lipoprotein (VLDL). Moreover, mem-
brane sortilin acts as a receptor for circulating LDL, pro-
moting their uptake by hepatocytes via an LDL-receptor 
(R)-independent mechanism [13–17]. After the discovery 
of its link to atherosclerosis, there has been considerable 
interest in elucidating additional functions of sortilin in 
different cell types. Thus, sortilin has been discovered to 
play a role in intracellular cytokine traffic [18, 19] and to 
be expressed in platelets, from where it is released after 
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activation [20]. Among those additional roles, the sortilin 
function as a membrane LDL-R has been implicated in 
LDL uptake by macrophages and in foam cell formation 
and directly in inflammatory mechanisms during ath-
erosclerotic plaque formation and progression [21, 22]. 
Additionally, sortilin seems to be a fundamental player in 
hepatic and muscular response to insulin and may be a 
missing link between insulin resistance and hypercholes-
terolemia [23–25].
Aside from its potential as a therapeutic target, sortilin 
has been found in increased quantities in patients with 
coronary artery disease (CAD) and in patients with CAD 
risk factors compared to control subjects [20, 26].
Peripheral artery disease (PAD) is a well-known mani-
festation of atherosclerosis, which is associated with 
considerable disability and mortality. Lower limb PAD 
(LL-PAD) is of particular concern in diabetic patients 
and in active or current smokers, where the incidence 
and prevalence of the disease are particularly high. 
Ankle-brachial index (ABI) is currently recommended 
as the main screening tool for PAD in diabetic patients 
and in those with multiple risk factors [27]. A reduction 
in ABI, however, represents an already clinically signifi-
cant stage of the disease. A tool used to find patients with 
higher risk of developing significant LL-PAD would be 
useful in identifying patients at a particularly high risk 
of developing clinically significant PAD and in tailoring 
more aggressive preventive and diagnostic strategies.
Considering the already proven links between the 
sortilin and multiple aspects of atherosclerosis [28, 29], 
metabolic imbalance [30] and diabetes [31], it is possible 
to hypothesize a connection between sortilin and PAD in 
the diabetic scenario.
Methods
The aim of this study was to assess the possible role of 
sortilin as an easy-to-measure marker for the presence of 
LL-PAD in an in-patient population with type 2 diabetes 
mellitus (T2DM).
Study design
We performed a cross-sectional study which was 
approved by the Ethics Committee of the Fondazione 
Policlinico Universitario A. Gemelli IRCCS and adhered 
to the principles of the Declaration of Helsinki. All the 
individuals agreed to participate in the study and gave 
informed consent. We analyzed the diabetic patients 
consecutively admitted to the Department of Vascular 
Diseases of the Fondazione Policlinico Universitario A. 
Gemelli IRCCS, Roma, Italy, from October 1, 2015 to Jan-
uary 30, 2018. Each patient admitted to the unit during 
the study time was evaluated for the enrollment in the 
present study. To be enrolled, each patient had to fulfill 
the criteria shown in Table 1.
We enrolled diabetic patients with or without PAD. 
Type 2 diabetes mellitus was defined as a fasting plasma 
glucose ≥ 126  mg/dL and/or HbA1c ≥ 6.5% or as medi-
cal history for the presence of diabetes plus treatment 
with diabetes medication. Each patient enrolled in the 
study had his/her medical history assessed for the pres-
ence of PAD symptoms or a confirmed PAD diagnosis. 
For each diabetic patient evaluated in the study, ABI was 
performed. Patients with clinical findings consistent with 
PAD underwent ABI measurement and either lower limb 
arterial Doppler-enhanced ultrasonography, lower limb 
angiography or computed tomography (CT)-angiogra-
phy, at the attending physician’s judgment. The patients 
with a > 0.90 ABI measurement and without symptoms of 
PAD did not undergo further testing and were deemed to 
be without PAD.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
18 years and older Undefined type of diabetes or clinical suspi-
cion of non-type 2 diabetes mellitus
Confirmed diagnosis of 
type 2 diabetes mellitus 
at the time of admission
Confirmed pancreatic insufficiency, chronic 
pancreatitis or previous pancreatic 
surgery
Able to understand study 
procedures
Ongoing steroidal therapy or steroidal 
therapy in the previous 3 months
Willing to participate in 
the study and to sign the 
written informed consent
Ongoing calcineurin inhibitor therapy or 
history of calcineurin inhibitor therapy
Ongoing statin therapy or statin therapy in 
the previous month
Suspected or confirmed pregnancy
Chronic kidney disease with eGFR below 
30 mL/min (according to the CKD-EPI 
equation)
Previous non-traumatic lower limb amputa-
tion
Solid organ or marrow transplant recipient
History or active solid or hematological 
malignancy
Acute infectious disease at the time of 
evaluation or in the previous month
Chronic liver disease with a functional 
status, according to the Child–Pugh clas-
sification, of B or above
Hereditary monogenic dyslipidemia (con-
firmed or suspected)
Congenital disease of platelet function
Acquired or congenital thrombocytopenia
Congenital or acquired hemophilia or 
coagulation defect
Congenital or acquired thrombophilia
Active autoimmune disease
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The patients were considered to have PAD if:
• They had had a history of previous lower limb per-
cutaneous transluminal angioplasty, with or without 
stent placement, or
• They had had at least one instrumental and one clini-
cal criterion among those listed in Table 2.
Such criteria were consistent with published literature 
[32–35].
The extent of PAD was determined by using the Fon-
taine classification, which defines four stages:
Stage I, asymptomatic; stage II, intermittent claudica-
tion; stage III, rest pain; stage IV ischemic ulcers or gan-
grene [36, 37].
Biochemical measurement
All patients enrolled underwent a blood test after an 
overnight fasting period of 8 h. For every patient, fasting 
glucose, triglycerides, total cholesterol, low and high-den-
sity lipoprotein, creatinine, aspartate aminotransferase, 
alanine aminotransferase, total bilirubin, alkaline phos-
phatase and complete blood count were determined. 
Renal function was assessed using estimated glomerular 
filtration rate (eGFR), which was calculated using the 
modification of diet in renal disease (MDRD) formula, 
as previously described [38]. Serum obtained and sepa-
rated by centrifugation of blood samples was stored at 
− 80  °C before every measurement. Serum sortilin level 
were determined by a commercially available ELISA kit 
(RAB1709 SIGMA, Sigma-Aldrich) according to its pro-
tocol. The intra and inter-assay coefficients of variation 
were 3.5 and 10.5%, respectively. The sensitivity, defined 
as the mean ± 3 SD of the 0 standard, was calculated to 
be 0.15 pmol/mL. For each patient, the serum levels were 
measured twice and the results were averaged.
Statistical analysis
Demographic and clinical data between the groups were 
compared using Chi squared and t tests. Sortilin serum 
levels were compared through Mann–Whitney test. A 
log transformation was applied to not-normally distrib-
uted variables (fasting glucose, glycated hemoglobin, 
triglyceride, and sortilin levels) prior to performing fur-
ther analysis. A multivariate stepwise logistic regression 
analysis was performed, adjusted for traditional risk fac-
tors and sortilin levels. The area under the receiver-oper-
ating characteristics (ROC) curve was calculated to test 
its predictive discrimination of PAD. All analyses were 
performed using the STATA version 11.0 for Windows 
(Statistics/Data Analysis, Stata Corporation, College Sta-
tion, TX, USA). Statistical significance was established at 
P < 0.05.
Results
During the study period, 154 patients with a con-
firmed diagnosis of T2DM and not on statin therapy in 
the last 30  days, were included in the study. Eighty of 
the patients did not fulfill the criteria for a diagnosis of 
PAD, while the remaining 74 had a confirmed diagnosis 
of PAD or received a diagnosis of PAD during the index 
hospitalization. The demographic and clinical charac-
teristics of the two groups are reported in Table 3. PAD 
patients had higher blood pressure values (P = 0.024), 
were more often smokers (P = 0.032) and were affected 
by CAD (defined as history of ischemic heart disease 
and/or previous coronary revascularization) more fre-
quently (P = 0.031). There were no significant differ-
ences between groups regarding body mass index (BMI) 
(P = 0.52), median duration of diabetes (P = 0.97), fasting 
glucose (P = 0.75), glycated hemoglobin (P = 0.59), total 
cholesterol (TC) (P = 0.78), HDL-cholesterol (P = 0.67), 
LDL-cholesterol (P = 0.73) and triglyceride (P = 0.99). No 
statistical difference in terms of eGFR (P = 0.12), aspar-
tate aminotransferase (P = 0.61), alanine aminotrans-
ferase (P = 0.45), total bilirubin (P = 0.33) and alkaline 
phosphatase (P = 0.56). Furthermore, there were no sig-
nificant differences between groups regarding the com-
plete blood count (Table  3). No statistical difference in 
terms of diabetic therapy was observed between the two 
Table 2 Criteria for PAD definition in patients without a history of lower limb amputation, PTA or by-pass surgery
Clinical Criteria Instrumental criteria
Presence of claudication intermittens ABI < 0.90
Rest pain TcPO2 < 30 mmHg
Non-healing distal ulcer Ultrasonographic or radiologic finding of atherosclerotic narrowing, with a reduction of 
at least 50% of the lumen diameter, consistent with clinical symptoms
Gangrene Ultrasonographic finding of post-stenotic blood flow profile, consistent with symptoms
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patient groups. According to the Fontaine’s classification 
36 patients were defined as stage II, 24 as stage III and 14 
as stage IV.
Sortilin concentration was higher among patients with 
PAD than among those without PAD (1.61 ± 0.54  ng/
mL versus 0.67 ± 0.30 ng/mL, P < 0.01), as highlighted in 
Fig. 1. Moreover, when evaluating sortilin concentration 
according to patients’ functional status, a trend was evi-
dent, with higher levels of circulating sortilin in patients 
with more advanced disease (Fig. 2).
The multivariate logistic regression analysis showed 
that, after adjustments for cardiovascular risk factors, 
male gender, smoking, hypertension, hyperlipidemia, 
total cholesterol, HDL-cholesterol, LDL-cholesterol and 
sortilin levels were independent determinants for PAD 
occurrence in patients with T2DM (Table 4).
The ability of the area under the ROC curve based on 
sortilin levels to predict the presence of PAD in diabetic 
patients was 0.9133 (Fig. 3).
Discussion
The ABI is a very commonly used tool, easy to oper-
ate and it is able to identify PAD very effectively. When 
ABI is suggestive of PAD, however, we are often faced 
with a patient with an already advanced disease [39]. If 
we consider that PAD in diabetic patients can be even 
more aggressive and can manifest the symptoms later, the 
Table 3 Demographic and  clinical data of  diabetic 
subjects with and without PAD
Data are number (%) and standard deviation (SD)
WPAD PAD P value
(n = 80) (n = 74)
Male (%) 69 65 0.34
Age (years ± SD) 73.1 ± 6.4 69.8 ± 6.3 0.89
Body mass index (kg/m2) 24.3 ± 2.1 23.9 ± 2.8 0.52
Smoking (current) (%) 17 (21.25) 19 (25.67) 0.032
Hypertension (%) 35 (44.0) 47 (63.5) 0.024
Coronary artery disease (%) 25 (31.2) 39 (52.7) 0.031
Diabetes duration (years ± SD) 10.1 ± 6.1 11.6 ± 5.9 0.97
Total cholesterol (mmol/L) 5.97 (1.81) 5.87 (1.35) 0.78
HDL-cholesterol (mmol/L) 1.24 (1.21) 1.20 (1.21) 0.67
LDL-cholesterol (mmol/L) 2.82 (1.08) 2.78 (0.83) 0.73
Triglyceride (mmol/L) 2.32 (1.67) 1.98 (1.12) 0.99
Fasting glucose (mmol/L) 7.19 (1.12) 7.61 (1.85) 0.75
Glycated hemoglobin (%) 7.13 (1.41) 7.21 (1.84) 0.59
eGFR (mL/min per 1.73 m2) 72.12 (8.19) 67.98 (6.76 0.12
Aspartate aminotransferase (UI/L) 38.2 (4.5) 34.4 (3.8) 0.61
Alanine aminotransferase (UI/L) 41.1 (4.9) 44.3 (3.9) 0.45
Total bilirubin (mg/dL) 0.9 (0.3) 1.1 (0.4) 0.33
Alkaline phosphatase (UI/L) 109.6 (12.3) 112.3 (9.4) 0.56
Hemoglobin (g/dL) 11.6 (2.12) 12.1 (2.01) 0.98
White blood cells (× 10E3/μL) 5.9 (0.68) 6.1 (0.98) 0.85
Platelets (× 10E3/μL) 254 (15.2) 236 (17.3) 0.52
Treatment
 Diet only (%) 9 (11.25) 11 (14.86) 0.76
 Oral agents (%) 42 (52.5) 38 (51.35) 0.88
 Insulin therapy (%) 38 (47.5) 35 (47.29) 0.65
PAD
 1-Fontaine’s II (%) 36 (48.64)
 2-Fontaine’s III (%) 24 (32.43)
 2-Fontaine’s IV (%) 14 (18.91)
Fig. 1 Sortilin levels according to PAD diagnosis. On the box plots, 
central lines represent the median, the length of the box represents 
the interquartile range and the lines extend to minimum and 
maximum values
Fig. 2 Sortilin levels according to PAD severity. On the box plots, 
central lines represent the median, the length of the box represents 
the interquartile range and the lines extend to minimum and 
maximum values
Page 5 of 8Biscetti et al. Cardiovasc Diabetol            (2019) 18:5 
research for tools useful for an early diagnosis appears 
essential [40]. There are some potential biomarkers able 
to identify a subset of diabetic patients with PAD more 
prone to suffer major amputations; for instance, the 
tumor necrosis factor receptor 1 (TNFR1) has been asso-
ciated with major amputation outcome [41]. Another 
possible biomarker for the presence of PAD in diabetic 
patients is represented by the high mobility group box 1 
(HMGB1) which, together with the osteoprotegerin 
(OPG), has been associated with the presence of PAD 
in these patients [42]. Furthermore, also the fibroblast 
growth factor (FGF) 23 has been correlated with the 
presence of lower extremity atherosclerotic disease in 
diabetic patients [43]. In this scenario, sortilin may be of 
clinical interest as a simple, easy to measure biochemical 
marker for atherosclerotic disease. Numerous evidence 
suggests that sortilin is implicated in the pathogenesis 
of many inflammatory and metabolic diseases, includ-
ing T2DM and atherosclerotic complications of diabetes 
[31]. In addition, sortilin has been shown to be an ener-
getic regulator of lipid metabolism [44]. No definitive 
data about the role of sortilin in atherosclerosis and dia-
betes, however, are available. We have evidence that sor-
tilin is decisive in the formation of atherosclerotic plaque 
and that therapeutic agents capable of reducing serum 
sortilin levels are able to improve atherosclerosis [30]. 
Sortilin-dependent uptake of LDL into macrophages 
represents an interesting mechanism of foam cell forma-
tion, the fundamental lesion of atherosclerotic disease 
[21]. There are data demonstrating that liver sortilin, 
however, could play a positive role in atherosclerosis, 
improving cholesterol metabolism and reducing LDL 
levels, which are fundamental players in the formation 
of atherosclerotic lesion [15]. Recent data have shown 
that a process dependent on autophagy degrades apoB 
that was diverted from the secretory pathway by sortilin 
and provides a mechanism contributing to the reduction 
of LDL cholesterol [45]. It is therefore possible that sor-
tilin performs different functions depending on the dis-
trict where it is produced, on the receptors which it binds 
and on the extracellular milieu where it is released. Oh 
and colleagues [26] have shown that this protein is asso-
ciated with coronary artery disease and diabetes. To our 
knowledge, this is the first time that the sortilin serum 
concentration has been assessed as a potential biomarker 
for peripheral atherosclerotic artery disease of the 
lower limbs in a diabetic population. Our study shows a 
strong correlation between sortilin concentration and 
lower limb clinically significant atherosclerotic disease 
in T2DM patients. Previous experimental evidence has 
shown that sortilin is involved in the formation of ath-
erosclerotic plaque. In particular, in a mouse model it 
has been shown that sortilin facilitates plaque formation 
by promoting the inflammatory setting [22]. It is there-
fore possible that in our population of diabetic patients, 
high sortilin values are responsible, at least in part, for 
atherosclerotic lesions of the lower limbs. An additional 
important data is that the levels of sortilin correlate with 
the PAD severity in diabetic patients, as if there were a 
dose-dependent relationship. Of particular interest, 
there is very little overlap between sortilin concentration 
in patients with PAD and in patients without PAD. The 
ROC curve also confirms that sortilin levels are able to 
predict the presence of PAD in our population of diabetic 
patients. If such result was confirmed, sortilin concentra-
tion could prove a biomarker with excellent sensitivity 
and specificity for peripheral artery disease in diabetic 
subjects.
A strength of this study is the fact that we enrolled only 
patients who were not on statin therapy. Given that sta-
tin therapy may affect sortilin concentration, our result, 
thus, are unlikely to be due to interference of pharmaco-
logical therapy. On the other hand, as many patients with 
diabetes or at high cardiovascular risk are more likely to 
Table 4 Multivariable stepwise logistic regression 
model for  presence of  PAD for  common risk factors 
and for sortilin
Variable OR (95% CI) P value
Age 1.13 (0.9–1.21) 0.187
Men 1.98 (1.12–2.78) < 0.001
Smoking 33.51 (8.22–145.27) < 0.001
Hypertension 19.97 (6.36–67.61) < 0.001
Hyperlipidemia 18.42 (5.15–31.38) 0.003
Total cholesterol 1.13 (0.98–2.14) 0.012
HDL-cholesterol 0.09 (0.02–0.18) 0.211
LDL-cholesterol 11.33 (4.15–62.14) 0.055
Sortilin 5.21 (1.92–18.32) 0.003
Fig. 3 ROC curve analysis of the ability of sortilin to predict the 
presence of PAD in diabetic patients
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be on statin therapy, our results need to be confirmed in a 
larger, more representative population. Statin therapy has 
been shown to reduce statin levels in patients with CAD 
[30]. Even circulating PCSK9 has been independently 
related to sortilin, and also their correlation is affected by 
the statin therapy [46]. Since our patient population was 
statin-free, the data we have documented are not affected 
by this aspect. At the same time, this finding could rein-
force the hypothesis of using this biomarker to stratify 
patients, both from a diagnostic and a therapeutic point 
of view. It would be justified to assess PAD in diabetic 
patients with higher sortilin levels and it would be useful 
to start a more aggressive statin treatment in this subset 
of patients.
It is not possible to definitively clarify whether sorti-
lin levels are a cause or effect of atherosclerosis, or even 
both, in a sort of vicious circle. The earlier studies on 
sortilin highlighted its causative role in atherosclerotic 
disease, mainly due to the action of intracellular sortilin. 
In fact, in the study by Musunuru and colleagues [15], 
protective SNP was associated with a reduced intracellu-
lar concentration of sortilin and it was this intracellular 
action that is thought as associated with atherosclerosis. 
It has been later shown, however, that sortilin is actively 
secreted by activated platelet and may play a role in 
foam-cell formation. Thus, circulating sortilin concentra-
tion may also be a consequence of atherosclerosis.
A limitation of our study is that its cross-sectional 
nature is not able to establish causal relationship between 
the findings. Even so, our result lend support to the 
hypothesis that sortilin actions in extra-hepatic tissue are 
important in the atherosclerosis physiopathology. A fur-
ther limitation is the small number of patients included 
in the study, due to the particular condition that required 
the presence of diabetes and the absence of statin treat-
ment. Another major limitation of our study is the lack 
of prospective data. We didn’t aim, however, to investi-
gate sortilin as a maker for increased risk, we tested it as 
a marker for active disease. A further limitation of our 
study is in that we chose to define PAD as a clinically 
apparent disease. In fact, to overcome this limitation a 
prospective study would be needed. We believe that our 
present result may lay the foundation for such a subse-
quent prospective study.
Conclusions
We demonstrated that circulating sortilin levels are asso-
ciated with PAD in diabetic patients, that sortilin levels 
correlate with disease severity and that, therefore, sor-
tilin is a promising marker for PAD in diabetic patients. 
Furthermore, in addition to risk factor-based validated 
scores, sortilin may help clinicians to better stratify 
atherosclerotic risk in diabetic patients. Further studies 
to confirm this hypothesis are needed and warranted.
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